<?xml version="1.0" encoding="UTF-8"?>
<p id="Par19">Additional observations that may test the predictions from in-silico reports implicating a role for sialic acid residues as SARS-CoV-2 receptors include (1) efficacy of the therapeutic use of lactoferrin
 <sup>
  <xref ref-type="bibr" rid="CR66">66</xref>
 </sup>, an antiviral agent that interacts with sialic acid residues; (2) an ongoing clinical trial of DAS181 (
 <ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT04324489" xmlns:xlink="http://www.w3.org/1999/xlink">https://clinicaltrials.gov/ct2/show/NCT04324489</ext-link>), a drug designed to block viral access by cleaving sialic acid; (3) that the shedding pattern of SARS-CoV-2 infection is different from that of SARS-CoV and more similar to that of “standard” influenza
 <sup>
  <xref ref-type="bibr" rid="CR66">66</xref>
 </sup>, where sialic acid receptors play a major role; (4) a bioinformatic study reports binding of S-protein to sialic acid glycans in a region close to that identified by the in silico studies
 <sup>
  <xref ref-type="bibr" rid="CR65">65</xref>,
  <xref ref-type="bibr" rid="CR67">67</xref>
 </sup>. To our knowledge, while links between sialic acid and neurotropism for mouse hepatitis virus
 <sup>
  <xref ref-type="bibr" rid="CR68">68</xref>
 </sup> and adenoviruses
 <sup>
  <xref ref-type="bibr" rid="CR69">69</xref>
 </sup> have been suggested, there are no published investigations on this alternative pathway for SARS-CoV-2 interaction in the nervous system.
</p>
